CardioSert News
4 articles
Microbot Medical Closes Acquisition of Novel Technology from CardioSert Ltd.
Microbot Medical Inc. has announced the acquisition of a novel patent-protected technology from CardioSert Ltd. The acquisition includes R&D information, technical know-how, and intellectual property. Microbot believes that the technology has the potential to be used in various medical applications. The company plans to leverage its existing capabilities, global IP, and recent pre-clinical results to develop highly differentiated robotic products. The acquisition was made in exchange for 100,000 restricted shares of Microbots common stock and a cash payment of $250,000, with potential additional milestone payments and earn-outs. Microbot Medical specializes in transformational micro-robotic medical technologies and is currently developing its first two product candidates: the Self Cleaning Shunt (SCS) and a self-propelling, semi-disposable endoscope. The company aims to address unmet medical needs and build a multi-generation product pipeline.
Acquisition
Microbot Medical Exercises Option to Acquire Novel Technology from CardioSert Ltd.
Microbot Medical Inc., a medical device company, has announced the acquisition of a novel patent-protected technology from CardioSert Ltd. The acquisition strengthens Microbots IP portfolio, creates additional barriers to entry, and expands its addressable markets. The technology has the potential to be used in various medical spaces and applications. The closing of the technology acquisition is expected in late April. Microbot will exchange 100,000 restricted shares of its common stock and a cash payment of $250,000 for CardioSerts technology. Microbot is focused on developing transformational micro-robotic medical technologies, with its current platforms being the Self Cleaning Shunt (SCS) and a self-propelling, semi-disposable endoscope. The company aims to increase shareholder value and deliver on its core promises.
Acquisition
Microbot Medical to Acquire CardioSert's Technology
Microbot Medical Inc. has entered into an agreement to acquire CardioSert Ltd.s patented guidewire technology. The acquisition is expected to close in April 2018 and will add to Microbots patent portfolio. CardioSerts technology offers capabilities such as steering and adjustable stiffness to guidewires used in medical procedures. Microbot believes the technology has applications in other medical spaces and will enhance its existing robotic capabilities. As part of the agreement, CardioSert will receive restricted shares of Microbots common stock, cash payments, milestone payments, and royalties from future sales.
Acquisition
MICROBOT MEDICAL INC. (NASDAQ:MBOT) Files An 8-K Entry into a Material Definitive Agreement
Microbot Medical Inc., a medical device company, has entered into an agreement to acquire certain patent-protected technology owned by CardioSert Ltd. The acquisition is expected to close in April 2018. Microbot will make an initial payment of $50,000 and has 90 days to complete the acquisition. The Technology will be added to Microbots patent portfolio, which will then have a total of 25 issued/allowed patents and 15 patent applications pending worldwide. The acquisition aligns with Microbots strategy to develop micro-robotic technologies for surgeries and expand its intellectual property portfolio. The agreement also includes future earn-out payments based on net sales of Type 1 and Type 2 products. CardioSert will receive milestone payments upon successful animal trials and FDA approval. The agreement may be terminated by either party under certain conditions. Microbot issued a press release on January 8, 2018, regarding the agreement.
Acquisition
